<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00118742</url>
  </required_header>
  <id_info>
    <org_study_id>ML18423</org_study_id>
    <nct_id>NCT00118742</nct_id>
  </id_info>
  <brief_title>Liver Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Sirolimus in Recipients of a Liver Transplant</brief_title>
  <official_title>A Randomized, Open-label Study of the Effect of a Long-term Calcineurin Inhibitor-free Maintenance Regimen With CellCept and Sirolimus on Preservation of Renal Function and Prevention of Acute Rejection in Recipients of an Orthotropic Liver Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <brief_summary>
    <textblock>
      This two-arm study will assess the efficacy and safety of a long-term calcineurin
      inhibitor-free maintenance regimen with CellCept and sirolimus in recipients of an
      orthotropic liver transplant. Patients will be randomized to receive either CellCept 1-1.5 g
      twice daily (BID) + tacrolimus + cyclosporine, or CellCept 1-1.5 g BID + sirolimus. The
      anticipated time on study treatment is 1 to 2 years, and the target sample size is 100 to 500
      individuals.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Glomerular Filtration Rate (GFR) at 12 Months Posttransplant</measure>
    <time_frame>12 months posttransplant</time_frame>
    <description>Mean percent change from baseline in estimated glomerular filtration rate (GFR) calculated by modification of diet in renal disease (MDRD)-6 variable equation at 12 months posttransplantation. MDRD-6 variables: serum creatinine, albumin and urea nitrogen, gender, age and ethnicity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Glomerular Filtration Rate (GFR) at 6 Months Posttransplant</measure>
    <time_frame>6 months posttransplant</time_frame>
    <description>Mean percent change from baseline in estimated GFR calculated by modification of diet in renal disease (MDRD)-6 variable equation at 6 and 24 months posttransplantation. MDRD-6 variables: serum creatinine, albumin and urea nitrogen, gender, age and ethnicity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Glomerular Filtration Rate (GFR) at 24 Months Posttransplant</measure>
    <time_frame>24 months posttransplant</time_frame>
    <description>Mean percent change from baseline in estimated GFR calculated by modification of diet in renal disease (MDRD)-6 variable equation at 6 and 24 months posttransplantation. MDRD-6 variables: serum creatinine, albumin and urea nitrogen, gender, age and ethnicity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Creatinine Clearance</measure>
    <time_frame>6, 12, and 24 months posttransplantation</time_frame>
    <description>Mean percent change from baseline in calculated creatinine clearance (CL) at 6, 12, and 24 months posttransplantation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">293</enrollment>
  <condition>Liver Transplantation</condition>
  <arm_group>
    <arm_group_label>CellCept + CNI (tacrolimus or cyclosporine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CellCept + sirolimus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate mofetil [CellCept]</intervention_name>
    <description>1-1.5 g orally or intravenously twice daily</description>
    <arm_group_label>CellCept + CNI (tacrolimus or cyclosporine)</arm_group_label>
    <arm_group_label>CellCept + sirolimus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>As prescribed, for 12 months</description>
    <arm_group_label>CellCept + CNI (tacrolimus or cyclosporine)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine</intervention_name>
    <description>As prescribed, for 12 months</description>
    <arm_group_label>CellCept + CNI (tacrolimus or cyclosporine)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sirolimus</intervention_name>
    <description>2-4 mg orally once daily for 9-11 months</description>
    <arm_group_label>CellCept + sirolimus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients 18-74 years of age

          -  Single primary liver transplant from a deceased donor

          -  CellCept plus tacrolimus or cyclosporine from time of transplantation (within 72
             hours)

          -  Patients with hepatitis C-positive status may be entered if they have had an
             intraoperative (back table) biopsy of the transplanted liver or will have a biopsy at
             the time of randomization. This is not required for patients negative for hepatitis C.

        Exclusion Criteria:

          -  Liver allograft from a living donor or a split liver

          -  Multiple organ transplant

          -  Dialysis therapy for &gt;14 days from transplantation to randomization

          -  History of malignancy in the last 5 years (except hepatoma or non-melanoma skin
             cancer)

          -  Previous sirolimus therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033-4612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103-8401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-0780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612-3824</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114-2696</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202-2689</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07101-1709</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hawthorne</city>
        <state>New York</state>
        <zip>10532</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112-4481</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97201-3098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78284</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 3A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 3J4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 1A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.roche-trials.com/studyResultGet.action?studyResultNumber=ML18423</url>
    <description>Clinical Study Report Synopsis</description>
  </link>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2005</study_first_submitted>
  <study_first_submitted_qc>July 11, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2005</study_first_posted>
  <results_first_submitted>May 13, 2009</results_first_submitted>
  <results_first_submitted_qc>February 19, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 10, 2010</results_first_posted>
  <last_update_submitted>July 30, 2010</last_update_submitted>
  <last_update_submitted_qc>July 30, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 3, 2010</last_update_posted>
  <responsible_party>
    <name_title>Disclosures Group</name_title>
    <organization>Hoffmann-La Roche</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Calcineurin Inhibitors</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited from 43 study centers in the US and Canada over a period of 3 years (24-Aug-05 to 03-Jul-08)</recruitment_details>
      <pre_assignment_details>Eligible for the study were adult patients (18 to 74 years) who had received a single primary orthotopic liver transplant and were receiving or were scheduled to receive treatment with CellCept® + calcineurin inhibitor (CNI)</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>CellCept + CNI (Tacrolimus or Cyclosporine)</title>
          <description>CellCept 1-1.5 g orally or intravenously twice daily, plus a calcineurin inhibitor (CNI) tacrolimus or cyclosporine for 12 months</description>
        </group>
        <group group_id="P2">
          <title>CellCept + Sirolimus</title>
          <description>CellCept 1-1.5 g orally or intravenously twice daily, plus sirolimus 2-4 mg orally once daily for 9-11 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="145"/>
                <participants group_id="P2" count="148"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
                <participants group_id="P2" count="82"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="66"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CellCept + CNI (Tacrolimus or Cyclosporine)</title>
          <description>CellCept 1-1.5 g orally or intravenously twice daily, plus a calcineurin inhibitor (CNI) tacrolimus or cyclosporine for 12 months</description>
        </group>
        <group group_id="B2">
          <title>CellCept + Sirolimus</title>
          <description>CellCept 1-1.5 g orally or intravenously twice daily, plus sirolimus 2-4 mg orally once daily for 9-11 months</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="145"/>
            <count group_id="B2" value="148"/>
            <count group_id="B3" value="293"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.4" spread="7.88"/>
                    <measurement group_id="B2" value="53.2" spread="8.83"/>
                    <measurement group_id="B3" value="53.3" spread="8.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="110"/>
                    <measurement group_id="B2" value="110"/>
                    <measurement group_id="B3" value="220"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian or Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="126"/>
                    <measurement group_id="B2" value="125"/>
                    <measurement group_id="B3" value="251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="173.6" spread="10.04"/>
                    <measurement group_id="B2" value="173.0" spread="10.26"/>
                    <measurement group_id="B3" value="173.3" spread="10.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79" spread="16.32"/>
                    <measurement group_id="B2" value="77.9" spread="17.56"/>
                    <measurement group_id="B3" value="78.4" spread="16.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Glomerular Filtration Rate (GFR) at 12 Months Posttransplant</title>
        <description>Mean percent change from baseline in estimated glomerular filtration rate (GFR) calculated by modification of diet in renal disease (MDRD)-6 variable equation at 12 months posttransplantation. MDRD-6 variables: serum creatinine, albumin and urea nitrogen, gender, age and ethnicity.</description>
        <time_frame>12 months posttransplant</time_frame>
        <population>intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>CellCept + CNI (Tacrolimus or Cyclosporine)</title>
            <description>CellCept 1-1.5 g orally or intravenously twice daily, plus a calcineurin inhibitor (CNI) tacrolimus or cyclosporine for 12 months</description>
          </group>
          <group group_id="O2">
            <title>CellCept + Sirolimus</title>
            <description>CellCept 1-1.5 g orally or intravenously twice daily, plus sirolimus 2-4 mg orally once daily for 9-11 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Glomerular Filtration Rate (GFR) at 12 Months Posttransplant</title>
          <description>Mean percent change from baseline in estimated glomerular filtration rate (GFR) calculated by modification of diet in renal disease (MDRD)-6 variable equation at 12 months posttransplantation. MDRD-6 variables: serum creatinine, albumin and urea nitrogen, gender, age and ethnicity.</description>
          <population>intent-to-treat population</population>
          <units>Percent change in GFR (mL/min)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="39.86"/>
                    <measurement group_id="O2" value="19.7" spread="40.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0012</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>24.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>14.8</ci_lower_limit>
            <ci_upper_limit>35.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Glomerular Filtration Rate (GFR) at 6 Months Posttransplant</title>
        <description>Mean percent change from baseline in estimated GFR calculated by modification of diet in renal disease (MDRD)-6 variable equation at 6 and 24 months posttransplantation. MDRD-6 variables: serum creatinine, albumin and urea nitrogen, gender, age and ethnicity.</description>
        <time_frame>6 months posttransplant</time_frame>
        <population>intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>CellCept + CNI (Tacrolimus or Cyclosporine)</title>
            <description>CellCept 1-1.5 g orally or intravenously twice daily, plus a calcineurin inhibitor (CNI) tacrolimus or cyclosporine for 12 months</description>
          </group>
          <group group_id="O2">
            <title>CellCept + Sirolimus</title>
            <description>CellCept 1-1.5 g orally or intravenously twice daily, plus sirolimus 2-4 mg orally once daily for 9-11 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Glomerular Filtration Rate (GFR) at 6 Months Posttransplant</title>
          <description>Mean percent change from baseline in estimated GFR calculated by modification of diet in renal disease (MDRD)-6 variable equation at 6 and 24 months posttransplantation. MDRD-6 variables: serum creatinine, albumin and urea nitrogen, gender, age and ethnicity.</description>
          <population>intent-to-treat population</population>
          <units>Percent change in GFR (mL/min)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="24.39"/>
                    <measurement group_id="O2" value="25.5" spread="45.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>25.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>15.7</ci_lower_limit>
            <ci_upper_limit>35.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Glomerular Filtration Rate (GFR) at 24 Months Posttransplant</title>
        <description>Mean percent change from baseline in estimated GFR calculated by modification of diet in renal disease (MDRD)-6 variable equation at 6 and 24 months posttransplantation. MDRD-6 variables: serum creatinine, albumin and urea nitrogen, gender, age and ethnicity.</description>
        <time_frame>24 months posttransplant</time_frame>
        <population>intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>CellCept + CNI (Tacrolimus or Cyclosporine)</title>
            <description>CellCept 1-1.5 g orally or intravenously twice daily, plus a calcineurin inhibitor (CNI) tacrolimus or cyclosporine for 12 months</description>
          </group>
          <group group_id="O2">
            <title>CellCept + Sirolimus</title>
            <description>CellCept 1-1.5 g orally or intravenously twice daily, plus sirolimus 2-4 mg orally once daily for 9-11 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Glomerular Filtration Rate (GFR) at 24 Months Posttransplant</title>
          <description>Mean percent change from baseline in estimated GFR calculated by modification of diet in renal disease (MDRD)-6 variable equation at 6 and 24 months posttransplantation. MDRD-6 variables: serum creatinine, albumin and urea nitrogen, gender, age and ethnicity.</description>
          <population>intent-to-treat population</population>
          <units>Mean percent change in GFR (mL/min)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="130"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.6" spread="43.37"/>
                    <measurement group_id="O2" value="13.5" spread="49.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0053</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>28.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>13.7</ci_lower_limit>
            <ci_upper_limit>43.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Creatinine Clearance</title>
        <description>Mean percent change from baseline in calculated creatinine clearance (CL) at 6, 12, and 24 months posttransplantation</description>
        <time_frame>6, 12, and 24 months posttransplantation</time_frame>
        <population>intent-to-treat population</population>
        <group_list>
          <group group_id="O1">
            <title>CellCept + CNI (Tacrolimus or Cyclosporine)</title>
            <description>CellCept 1-1.5 g orally or intravenously twice daily, plus a calcineurin inhibitor (CNI) tacrolimus or cyclosporine for 12 months</description>
          </group>
          <group group_id="O2">
            <title>CellCept + Sirolimus</title>
            <description>CellCept 1-1.5 g orally or intravenously twice daily, plus sirolimus 2-4 mg orally once daily for 9-11 months</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Creatinine Clearance</title>
          <description>Mean percent change from baseline in calculated creatinine clearance (CL) at 6, 12, and 24 months posttransplantation</description>
          <population>intent-to-treat population</population>
          <units>Percent change in creatinine CL (mL/min)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="145"/>
                <count group_id="O2" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="23.71"/>
                    <measurement group_id="O2" value="18.5" spread="39.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" spread="35.86"/>
                    <measurement group_id="O2" value="14.0" spread="35.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.8" spread="41.64"/>
                    <measurement group_id="O2" value="7.9" spread="44.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis for calculated creatinine clearance at 6 months posttransplant</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Median Difference (Final Values)</param_type>
            <param_value>21.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>12.5</ci_lower_limit>
            <ci_upper_limit>29.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis for calculated creatinine clearance at 12 months posttransplant</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>18.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>9.9</ci_lower_limit>
            <ci_upper_limit>26.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis for calculated creatinine clearance at 24 months posttransplant</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>23.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>10.2</ci_lower_limit>
            <ci_upper_limit>37.0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>CellCept + CNI (Tacrolimus or Cyclosporine)</title>
          <description>CellCept 1-1.5 g orally or intravenously twice daily, plus a calcineurin inhibitor (CNI) tacrolimus or cyclosporine for 12 months</description>
        </group>
        <group group_id="E2">
          <title>CellCept + Sirolimus</title>
          <description>CellCept 1-1.5 g orally or intravenously twice daily, plus sirolimus 2-4 mg orally once daily for 9-11 months</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Iron Deficiency Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Atrial Flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Mitral Valve Incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Ventricular Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Inappropriate Antidiuretic Hormone Secretion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Mouth Ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Umbilical Hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Abdominal Hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Crohn's Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Duodenitis Haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Inguinal Hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Inguinal Hernia, Obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Intestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Rectal Ulcer Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Small Intestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Multi-Organ Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Fat Tissue Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Hernia Obstructive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Impaired Healing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Ulcer Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Bile Duct Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Bile Duct Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Biliary Tract Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Hepatic Artery Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Autoimmune Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Haemobilia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Hepatic Artery Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Hepatic Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Hepatic Function Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Hepatic Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Hepatitis Acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Perforation Bile Duct</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Portal Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Transplant Rejection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Graft Versus Host Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Liver Transplant Rejection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Hepatitis C</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Clostridium Difficile Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Viral Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Abdominal Wall Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Acarodermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Clostridial Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Escherichia Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Lactobacillus Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Liver Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Lobar Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Pseudomonal Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Staphylococcal Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Subcutaneous Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Wound Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Incisional Hernia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Anastomotic Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Post Procedural Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Procedural Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Biliary Anastomosis Complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Complications of Transplanted Kidney</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Foot Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Graft Loss</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Meniscus Lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Post Procedural Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Rib Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Stress Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Vascular Pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hepatic Enzyme Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Blood Alkaline Phosphatase Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Blood Creatinine Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Blood Glucose Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Liver Function Test Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Diabetes Mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Spinal Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Hepatic Cancer Metastatic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>B-Cell Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Desmoid Tumour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Epstein-Barr Virus Associated Lymphoproliferative Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Tract Adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Hepatic Neoplasm Malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Non-Small Cell Lung Cancer Metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Renal Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Cerebral Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Haemorrhage Intracranial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Neuralgic Amyotrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Neuroleptic Malignant Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol Abuse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Confusional State</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Benign Prostatic Hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Alveolitis Allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Lung Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Pulmonary Oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Sinus Congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Drug Eruption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Embolism Venous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Orthostatic Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="134" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="141" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Mouth Ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Hepatitis C</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Incisional Hernia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Incision Site Pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hepatic Enzyme Increased</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Liver Function Test Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Weight Increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Weight Decreased</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>White Blood Cell Count Decreased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Blood Creatinine Increased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Muscle Spasms</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Night Sweats</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="148"/>
              </event>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="146"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="148"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>There were no overall limitations and caveats.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Hoffmann-La Roche</organization>
      <phone>800-821-8590</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

